SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to
Late last week, Atara Biotherapeutics Inc (NASDAQ: ATRA) announced that Bayer AG (OTC: BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted all
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Friday, 03/11/22, with the stock price down by -2.59% to the previous day’s close as strong demand from buyers drove the stock to $9.02. Actively observing the price movement in the last trading, the stock closed the session at $9.26, falling within a range of $9.00 … Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Good Pick For New Investors Now? Read More »
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2021 Results - Earnings Call Transcript
Atara Biotherapeutics press release (NASDAQ:ATRA): Q4 GAAP EPS of -$0.96 misses by $0.37.Revenue of $7.55M misses by $27.59M.
Tab-cel U.S. BLA Submission Not Currently Expected for Q2 2022 as Further FDA Engagement and Alignment Required; Anticipated EU Approval On-Track for Q4 2022 Under Accelerated Assessment
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics Q4 2021 Earnings Preview

10:35pm, Sunday, 27'th Feb 2022 Seeking Alpha
Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.69 (+27.4% Y/Y) and…
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Atara Biotherapeutics Stock Is Sinking Today

03:47pm, Friday, 18'th Feb 2022 The Motley Fool
A fatality in an early-stage clinical trial is weighing on the cell therapy company''s stock today.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE